COCP
Cocrystal Pharma, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.19
+4.39%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.16
From 52W high−24.20%
Volume67842.00
Market cap$22.92M
P/E (TTM)—
P/S (TTM)69.5x
Div yield—
Key dataSep 18, 2026
Open
$1.16
From 52W high
−24.20%
Volume
67842.00
Market cap
$22.92M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.3x
P/E (TTM)
—
RSI (14)
54.4
MomentumView details →
1D Return
+4.39%
YTD Return
+19.00%
SummaryUpdated Jun 1, 2026
Cocrystal Pharma, Inc. (NASDAQ:COCP) is a biotechnology company founded in 2008 and publicly traded since 2012. The company is headquartered in Bothell, Washington, and specializes in discovering and developing antiviral therapeutic treatments for serious and chronic viral diseases. Cocrystal employs structure-based drug design technologies to create novel antiviral compounds, with a primary focus on treating hepatitis C virus, influenza, coronavirus, and norovirus infections. The company operates as a clinical-stage biopharmaceutical firm with several drug candidates in various stages of development.
Similar companies
Latest newsMore news →
Cocrystal Pharma announced that the last subject has been dosed in its Phase 1b human challenge study evaluating CDI-988 as a potential preventive and treatment for norovirus infection.11d agoCocrystal Pharma, Inc. appointed Carol L. Brosgart as a director of the Company, effective August 12, 2026.34d ago